These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21362286)

  • 1. Cannabinoid receptor-2 selective antagonist negatively regulates receptor activator of nuclear factor kappa B ligand mediated osteoclastogenesis.
    Geng DC; Xu YZ; Yang HL; Zhu GM; Wang XB; Zhu XS
    Chin Med J (Engl); 2011 Feb; 124(4):586-90. PubMed ID: 21362286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of titanium particle-induced inflammatory osteolysis through inactivation of cannabinoid receptor 2 by AM630.
    Geng DC; Xu YZ; Yang HL; Zhu XS; Zhu GM; Wang XB
    J Biomed Mater Res A; 2010 Oct; 95(1):321-6. PubMed ID: 20623669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
    Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
    Cheng CP; Sheu MJ; Sytwu HK; Chang DM
    Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor.
    Chen T; Knapp AC; Wu Y; Huang J; Lynch JS; Dickson JK; Lawrence RM; Feyen JH; Agler ML
    Assay Drug Dev Technol; 2006 Aug; 4(4):387-96. PubMed ID: 16945012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
    Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells.
    Yoon WJ; Kim KN; Heo SJ; Han SC; Kim J; Ko YJ; Kang HK; Yoo ES
    Biochem Biophys Res Commun; 2013 May; 434(4):892-7. PubMed ID: 23611776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.
    Shim KS; Ma CJ; Kim DS; Ma JY
    J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
    Gong W; Dou H; Liu X; Sun L; Hou Y
    Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3.
    Duplomb L; Baud'huin M; Charrier C; Berreur M; Trichet V; Blanchard F; Heymann D
    Endocrinology; 2008 Jul; 149(7):3688-97. PubMed ID: 18403479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carvacrol Inhibits Osteoclastogenesis and Negatively Regulates the Survival of Mature Osteoclasts.
    Deepak V; Kasonga A; Kruger MC; Coetzee M
    Biol Pharm Bull; 2016 Jul; 39(7):1150-8. PubMed ID: 27170515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells.
    Ko SY
    Arch Oral Biol; 2012 Dec; 57(12):1623-32. PubMed ID: 22795564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipopolysaccharide (LPS) promotes osteoclast differentiation and activation by enhancing the MAPK pathway and COX-2 expression in RAW264.7 cells.
    Hou GQ; Guo C; Song GH; Fang N; Fan WJ; Chen XD; Yuan L; Wang ZQ
    Int J Mol Med; 2013 Aug; 32(2):503-10. PubMed ID: 23740407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.